Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome

American Journal of Medical Genetics, Part A

Volumn 155, Issue 4, 2011, Pages 805-810

  Cubells, Joseph F ^a   Deoreo, Elizabeth H ^a   Harvey, Philip D ^a   Garlow, Steven J ^a   Garber, Kathryn ^a   Adam, Margaret P ^a,b   Martin, Christa Lese ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

7 nicotinic acetylcholine receptor; Acetylcholine; Aggression; Autism; Chromosome disorders; Epilepsy; Mental retardation; Schizophrenia

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ARIPIPRAZOLE; BENZATROPINE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; ETIRACETAM; FLUOXETINE; GALANTAMINE; HALOPERIDOL; LITHIUM; LORAZEPAM; OLANZAPINE; OMEPRAZOLE; PREGABALIN; PROPRANOLOL; RIVASTIGMINE; ROPINIROLE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; AGGRESSION; AGITATION; ALZHEIMER DISEASE; AMMONIA BLOOD LEVEL; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CASE REPORT; CHRNA7 GENE; CHROMOSOME DELETION; CHROMOSOME DELETION 15Q13; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; FACE DYSMORPHIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; HYPERTENSION; INTELLECTUAL IMPAIRMENT; MALE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NEUROPATHIC PAIN; PARKINSONISM; PHARMACOGENETICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSIS; RAGE; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; VISUAL HALLUCINATION;

ADULT; CHOLINESTERASE INHIBITORS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 15; EPILEPSY; FEMALE; GALANTAMINE; HUMANS; MALE; MENTAL DISORDERS; PHARMACOGENETICS; PHENOTYPE; RAGE; SCHIZOPHRENIA; SYNDROME;

EID: 79953325912     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33917     Document Type: Article

References (30)

1. Adler LE, Hoffer LD, Wiser A, Freedman R. 1993. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856-1861.
2. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th edition. Text revision. Washington, DC: American Psychiatric Association Press.
3. Baldwin EL, Lee JY, Blake DM, Bunke BP, Alexander CR, Kogan AL, Ledbetter DH, Martin CL. 2008. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. Genet Med 10: 415-429.
4. Bassett AS, Chow EW. 1999. 22q11 deletion syndrome: A genetic subtype of schizophrenia. Biol Psychiatry 46: 882-891.
5. Ben-Shachar S, Lanpher B, German JR, Qasaymeh M, Potocki L, Nagamani SC, Franco LM, Malphrus A, Bottenfield GW, Spence JE, Amato S, Rousseau JA, Moghaddam B, Skinner C, Skinner SA, Bernes S, Armstrong N, Shinawi M, Stankiewicz P, Patel A, Cheung S-W, Lupski JR, Beaudet AL, Sahoo T. 2009. Microdeletion 15q13.3: A locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 46: 382-388.
6. Ben-Shachar SLB, German JR, Qasaymeh M, Potocki L, Sreenath Nagamani SC, Franco LM, Malphrus A, Bottenfield GW, Spence JE, Amato S, Rousseau JA, Moghaddam B, Skinner C, Skinner SA, Bernes S, Armstrong N, Shinawi M, Stankiewicz P, Patel A, Cheung S-W, Lupski JR, Beaudet AL, Sahoo T. 2010. Microdeletion 15q13.3: A locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 46: 382-388.
7. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP. 2008. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165: 82-89.
8. Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH. 1999. Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13). Hum Mol Genet 8: 1025-1037.
9. Dibbens LM, Mullen S, Helbig I, Mefford HC, Bayly MA, Bellows S, Leu C, Trucks H, Obermeier T, Wittig M, Franke A, Caglayan H, Yapici Z, Epicure C, Sander T, Eichler EE, Scheffer IE, Mulley JC, Berkovic SF. 2009. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: Precedent for disorders with complex inheritance. Hum Mol Genet 18: 3626-3631.
10. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. 1997. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587-592.
11. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR. 2008. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
12. Goebel RA, Sat P. 1975. Profile analysis and the abbreviated Wechsler Adult Intelligence Scale: a multivariate approach. J Consult Clin Psychol 43: 780-785.
13. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. 1998. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44: 98-106.
14. Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A, Muhle H, de Kovel C, Baker C, von Spiczak S, Kron KL, Steinich I, Kleefuss-Lie AA, Leu C, Gaus V, Schmitz B, Klein KM, Reif PS, Rosenow F, Weber Y, Lerche H, Zimprich F, Urak L, Fuchs K, Feucht M, Genton P, Thomas P, Visscher F, de Haan GJ, Møller RS, Hjalgrim H, Luciano D, Wittig M, Nothnagel M, Elger CE, Nürnberg P, Romano C, Malafosse A, Koeleman BP, Lindhout D, Stephani U, Schreiber S, Eichler EE, Sander T. 2009. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 41: 160-162.
15. International Schizophrenia Consortium. 2008. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455: 237-241.
16. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. 2002. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59: 1085-1096.
17. Leonard S, Mexal S, Freedman R. 2007. Smoking, genetics and schizophrenia: Evidence for self medication. J Dual Diagn 3: 43-59.
18. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M. 2001. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49: 279-288.
19. Mignon-Ravix C, Depetris D, Luciani JJ, Cuoco C, Krajewska-Walasek M, Missirian C, Collignon P, Delobel B, Croquette MF, Moncla A, Kroisel PM, Mattei MG. 2007. Recurrent rearrangements in the proximal 15q11-q14 region: A new breakpoint cluster specific to unbalanced translocations. Eur J Hum Genet 15: 432-440.
20. Miller DT, Shen Y, Weiss LA, Korn J, Anselm I, Bridgemohan C, Cox GF, Dickinson H, Gentile J, Harris DJ, Hegde V, Hundley R, Khwaja O, Kothare S, Luedke C, Nasir R, Poduri A, Prasad K, Raffalli P, Reinhard A, Smith SE, Sobeih MM, Soul JS, Stoler J, Takeoka M, Tan WH, Thakuria J, Wolff R, Yusupov R, Gusella JF, Daly MJ, Wu BL. 2009. Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet 46: 242-248.
21. Miller DT, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DN, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. 2010. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86: 749-764.
22. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. 2006. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
23. Pagnamenta AT, Wing K, Akha ES, Knight SJ, Bolte S, Schmotzer G, Duketis E, Poustka F, Klauck SM, Poustka A, Klauck SM, Poustka A, Ragoussis J, Bailey AJ, Monaco AP, International Molecular Genetic Study of Autism Consortium. 2009. A 15q13.3 microdeletion segregating with autism. Eur J Hum Genet 17: 687-692.
24. Pujana MA, Nadal M, Guitart M, Armengol L, Gratacos M, Estivill X. 2002. Human chromosome 15q11-q14 regions of rearrangements contain clusters of LCR15 duplicons. Eur J Hum Genet 10: 26-35.
25. Robinson WP, Dutly F, Nicholls RD, Bernasconi F, Penaherrera M, Michaelis RC, Abeliovich D, Schinzel AA. 1998. The mechanisms involved in formation of deletions and duplications of 15q11-q13. J Med Genet 35: 130-136.
26. Sharma T, Reed C, Aasen I, Kumari V. 2006. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res 85: 73-83.
27. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, Stevenson RE, Schroer RJ, Novara F, De Gregori M, Ciccone R, Broomer A, Casuga I, Wang Y, Xiao C, Barbacioru C, Gimelli G, Bernardina BD, Torniero C, Giorda R, Regan R, Murday V, Mansour S, Fichera M, Castiglia L, Failla P, Ventura M, Jiang Z, Cooper GM, Knight SJ, Romano C, Zuffardi O, Chen C, Schwartz CE, Eichler EE. 2008. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 40: 322-328.
28. Shinawi M, Schaaf CP, Bhatt SS, Xia Z, Patel A, Cheung SW, Lanpher B, Nagl S, Herding HS, Nevinny-Stickel C, Immken LL, Simpson Patel G, German JR, Beaudet AL, Stankiewicz P. 2009. A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat Genet 41: 1269-1271.
29. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, GROUP, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L, Collier DA, St Clair D, Stefansson K. 2008. Large recurrent microdeletions associated with schizophrenia. Nature 455: 232-236.
30. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, Nillesen WM, Innis JW, de Ravel TJ, Mercer CL, Fichera M, Stewart H, Connell LE, Ounap K, Lachlan K, Castle B, van der Aa N, can Revenswaaij C, Nobrega MA, Serra-Juhe C, Simonic I, de Leeuw N, Pfundt R, Bongers EM, Baker C, Finnemore P, Huang S, Maloney VK, Crolla JA, van Kamthout M, Elia M, Vandeweyer G, Fryns JP, Janssens S, Foulds N, Reitano S, Smith K, Perkel S, Loeys B, Woods CG, Oostra A, Speleman F, Pereira AC, Kurg A, Willatt L, Knight SJL, Vermeesch JR, Romano C, Barber JC, Mortier G, Perez-Jurado LA, Kooy F, Brunner HG, Eichler EE, Keefstra T, de Vries BBA. 2009. Further delineation of the 15q13 microdeletion and duplication syndromes: A clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet 46: 511-523.